Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02481830) enrolled 569 people in total — 284 in Group A and 285 in Group B. The trial was measuring how long participants lived overall, how long it took for their condition to worsen or progress, and what proportion of participants saw their tumours shrink or disappear. Participants went through a pre-treatment period before moving into the treatment period of the trial. The reported data shows the following figures. For overall survival — that is, the time from when someone joined the trial until death — the median (the midpoint value, where half of participants fell above and half below) was 7.46 months for Group A and 8.38 months for Group B. For progression-free survival — the time until the condition was recorded as getting worse or until death — the reported median was 1.45 months for Group A and 3.71 months for Group B. For objective response rate — the percentage of participants whose tumours were recorded as having shrunk by a meaningful amount or disappeared entirely — the reported figures were 13.7% in Group A and 16.8% in Group B. An additional analysis using extended data collection reported the same overall survival figures of 7.46 months and 8.38 months for Group A and Group B respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lung Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with small cell lung cancer (SCLC), confirmed through a tissue or cell sample test.
- Your cancer was classified as either "limited stage" (cancer confined to one area) or "extensive stage" (cancer that has spread more widely) when you were first diagnosed.
- Your cancer has come back or gotten worse after receiving a first treatment that included platinum-based chemotherapy, with or without radiation.
- You are generally in good health and able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required).
Who may not be able to join:
- You have cancer that has spread to the brain or spinal cord that has not yet been treated, or that is currently causing symptoms.
- You have previously received certain types of immunotherapy drugs, including those targeting PD-1, PD-L1, PD-L2, CD137, or CTLA-4 (confirm with trial site if you are unsure which treatments you have had).
- Your blood counts or liver function are not at a healthy enough level (confirm with trial site for specific values).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.